Early-stage clinical development risk
The company is still testing whether rese-cel can show safety and efficacy across autoimmune indications.
- Scope
- Lead programs and pipeline value
- Materiality
- high
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases. Its core platform, CABA, is designed to selectively eliminate disease-causing B cells and plasma cells, with lead programs such as rese-cel being studied in indications including pemphigus vulgaris, myositis, systemic lupus erythematosus, generalized myasthenia gravis, systemic sclerosis, and related autoimmune disorders. The company has not yet generated product revenue and remains focused on advancing clinical trials, regulatory interactions, and manufacturing readiness. Cabaletta is also building a commercial-scale manufacturing strategy through CDMO partnerships and potential internal capabilities to support future supply if its programs are approved.
2.77
2.77
| % | |
|---|---|
| Lead cell therapy candidate | 0% Autologous engineered T-cell therapy programs centered on rese-cel for autoimmune diseases. |
| Clinical development programs | 0% RESET-branded clinical studies evaluating rese-cel across multiple autoimmune indications. |
| Platform technology | 0% The CABA platform used to design and advance targeted cell therapies against pathogenic B cells and plasma cells. |
| Manufacturing and process development | 0% Process transfer, scale-up, and supply-chain readiness work with CDMOs and potential internal facilities. |
Cabaletta does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites,...
- Clinical trial patientsprimary
Patients with autoimmune diseases such as pemphigus vulgaris, myositis, SLE, MG, and systemic sclerosis who enroll in RESET studies to access investigational therapy.
- Clinical investigators and trial sitesprimary
Academic and specialty centers that recruit, treat, and monitor patients in Cabaletta’s clinical programs.
- Specialty autoimmune physicianssecondary
Rheumatologists, neurologists, dermatologists, and related specialists who would prescribe or refer patients if products are approved.
- Hospitals and treatment centerssecondary
Centers capable of handling cell therapy administration, monitoring, and patient support for complex autoimmune indications.
- Payers and reimbursement decision-makerssecondary
Insurers and health systems that would determine access and coverage for a high-cost advanced therapy.
Cabaletta is headquartered in the United States and its reported operating footprint is centered on U.S...
- •Headquartered in the United States
- •Clinical development and corporate operations are primarily U.S.-based
- •International operations are mentioned in headcount and cost growth
- •Manufacturing depends on third-party partners such as Lonza and Minaris
- •No product revenue has been generated, so no country revenue mix is disclosed
Cabaletta’s strategy is to advance rese-cel through multiple RESET clinical trials and build enough clinical evidence...
01
Advance lead clinical programsshort-term
Clinical proof-of-concept is the main value driver for a pre-revenue biotech and is required for any regulatory path.
02
Build scalable manufacturing capabilityshort-term
Cell therapy commercialization depends on reliable, compliant, and scalable supply.
03
Broaden platform applicabilitymedium-term
Multiple autoimmune indications can diversify clinical risk and increase the long-term commercial opportunity.
04
Maintain financing flexibilityshort-term
The company expects continued cash burn before any product revenue and needs capital to fund trials and manufacturing.
Cabaletta faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the possibility...
Manufacturing and supply chain dependence
Cabaletta relies on CDMOs and third parties for production, release testing, and process transfer.
- Scope
- Clinical supply and future commercialization
- Materiality
- high
Competition in autoimmune therapeutics
Other biopharmaceutical companies are developing therapies for PV, MG, SLE, myositis, SSc, gMG, and MS.
- Scope
- Market share, pricing, and physician adoption
- Materiality
- medium
Financing and dilution risk
The company has no product revenue and will need additional capital to fund trials and manufacturing scale-up.
- Scope
- Shareholder dilution and liquidity
- Materiality
- high
Research and development expense recognition
Can cause significant quarterly fluctuation in operating expenses and cash burn
Stock-based compensation
Affects reported operating loss and comparability across periods
Lease accounting for manufacturing arrangements
Impacts leverage presentation and operating cost structure
Interest income on cash and investments
Can partially offset operating losses and vary with cash deployment timing
: 28.4.2026